DeepMed Research

TUFTS MEDICAL CENTER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Supporting Mothers of Preterm Infants

Not Applicable

Completed

Conditions: PreTerm Birth

Interventions: Other: Limited Financial Support

First Posted Date: 2017-01-06

Last Posted Date: 2019-07-09

Lead Sponsor: Tufts Medical Center

Target Recruit Count: 68

Registration Number: NCT03013660

Locations: 🇺🇸
Tufts Medical Center, Boston, Massachusetts, United States
🇺🇸
Lowell General Hospital, Lowell, Massachusetts, United States

Clinical Hemodynamic Study of Balloon Counterpulsation in Advanced Heart Failure

Not Applicable

Completed

Conditions: Heart Failure

Interventions: Device: Conductance catheterization

First Posted Date: 2016-12-23

Last Posted Date: 2017-05-31

Lead Sponsor: Tufts Medical Center

Target Recruit Count: 15

Registration Number: NCT03001674

Locations: 🇺🇸
Tufts Medical Center, Boston, Massachusetts, United States

Trial of Venetoclax (ABT-199) and Dexamethasone for Relapsed or Refractory Systemic AL Amyloidosis

Phase 1

Terminated

Conditions: AL Amyloidosis

Interventions: Drug: Venetoclax
Drug: Dexamethasone

First Posted Date: 2016-12-22

Last Posted Date: 2020-08-21

Lead Sponsor: Tufts Medical Center

Target Recruit Count: 3

Registration Number: NCT03000660

Locations: 🇺🇸
Tufts Medical Center, Boston, Massachusetts, United States

Naloxegol to Prevent Lower Gastrointestinal Paralysis in Critically Ill Adults Administered Opioids

Phase 4

Terminated

Conditions: Constipation

Interventions: Drug: Placebo Oral Tablet
Drug: Naloxegol Oral Tablet
Drug: Docusate Sodium 100 Mg oral capsule [Colace]
Drug: Senna 217 Mg Oral Tablet
Drug: Polyethylene Glycols
Drug: Bisacodyl 10 mg Suppository
Drug: Magnesium Citrate Oral Liquid Product
Drug: Methylnaltrexone

First Posted Date: 2016-11-30

Last Posted Date: 2023-02-16

Lead Sponsor: Tufts Medical Center

Target Recruit Count: 12

Registration Number: NCT02977286

Locations: 🇺🇸
Tufts Medical Center, Boston, Massachusetts, United States

Topical Ruxolitinib for the Treatment of Vitiligo

Phase 2

Completed

Conditions: Vitiligo

Interventions: Drug: Ruxolitinib 1.5% Phosphate Cream

First Posted Date: 2016-06-22

Last Posted Date: 2020-08-31

Lead Sponsor: Tufts Medical Center

Target Recruit Count: 11

Registration Number: NCT02809976

Locations: 🇺🇸
Tufts Medical Center, Boston, Massachusetts, United States

Do Single Use Negative Pressure Dressings Reduce Wound Complications in Obese Women After Cesarean Delivery

Not Applicable

Terminated

Conditions: Obesity
Surgical Site Infections
Complications; Cesarean Section
Wound Complications

Interventions: Device: Negative Pressure Wound Therapy Dressing
Device: Standard Dressing

First Posted Date: 2016-06-15

Last Posted Date: 2021-02-21

Lead Sponsor: Tufts Medical Center

Target Recruit Count: 110

Registration Number: NCT02799667

Locations: 🇺🇸
Tufts Medical Center, Boston, Massachusetts, United States

A Diagnostic Screening Trial Seeking AL Amyloidosis Very Early

Completed

Conditions: Monoclonal Gammopathy
Plasma Cell Dyscrasia

First Posted Date: 2016-04-18

Last Posted Date: 2020-05-11

Lead Sponsor: Tufts Medical Center

Target Recruit Count: 20

Registration Number: NCT02741999

Locations: 🇺🇸
Tufts Medical Center, Boston, Massachusetts, United States

Airway Changes in Patients Undergoing Elective Surgical Procedures in the Prone and Trendelenburg Positions

Active, not recruiting

Conditions: Airway Management

First Posted Date: 2016-04-14

Last Posted Date: 2025-02-28

Lead Sponsor: Tufts Medical Center

Target Recruit Count: 180

Registration Number: NCT02738788

Locations: 🇺🇸
Tufts Medical Center, Boston, Massachusetts, United States

Safety of PZ-128 in Subjects Undergoing Non-Emergent Percutaneous Coronary Intervention

Phase 2

Completed

Conditions: Arterial Occlusive Diseases
Coronary Artery Disease
Coronary Disease
Arteriosclerosis
Heart Diseases
Myocardial Ischemia
Vascular Diseases
Acute Coronary Syndrome

Interventions: Drug: Placebo
Drug: PZ-128

First Posted Date: 2015-09-25

Last Posted Date: 2025-04-16

Lead Sponsor: Tufts Medical Center

Target Recruit Count: 100

Registration Number: NCT02561000

Locations: 🇺🇸
UMass Memorial Medical Center, Worcester, Massachusetts, United States
🇺🇸
Tufts Medical Center, Boston, Massachusetts, United States
🇺🇸
Inova Heart and Vascular Institute, Inova Fairfax Hospital, Falls Church, Virginia, United States

Minimal Residual Disease as a Possible Predictive Factor for Relapse in Patients With AL Amyloidosis

Completed

Conditions: Primary Amyloidosis
Amyloidosis

First Posted Date: 2015-09-22

Last Posted Date: 2020-08-24

Lead Sponsor: Tufts Medical Center

Target Recruit Count: 56

Registration Number: NCT02555969

Locations: 🇺🇸
Tufts Medical Center, Boston, Massachusetts, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy